PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Fetal Medicine
DOI: 10.1055/s-0045-1809044
Original Article

Clinical Utility of sFlt/PlGF Ratio in the Management of Hypertensive Disorders of Pregnancy: A Retrospective Cohort Study in a Tertiary Care Center

Tanisha Gupta
1   Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
,
K. Aparna Sharma 
1   Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
,
Anubhuti Rana
1   Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
,
Garima Wadhwa
1   Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
,
Vatsla Dadhwal
1   Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objectives

Hypertensive disorders of pregnancy (HDP) remain significant contributors to maternal and neonatal morbidity and mortality. These conditions arise from an imbalance between pro- and antiangiogenic factors from the placenta. The soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio has emerged as a promising biomarker for predicting preeclampsia and its complications. This study evaluates the clinical utility of the sFlt-1/PlGF ratio in predicting adverse outcomes and guiding management.

Methods

In this observational cohort study, pregnant women, either diagnosed with or at high risk for HDP, were recruited. Serum levels of sFlt-1 and PlGF were measured, and patients were classified into two groups based on a cutoff ratio of 38. Strict fetomaternal surveillance was done until delivery. Statistical analyses included comparisons of outcomes between groups and the predictive performance of the sFlt-1/PlGF ratio using receiver operating characteristic (ROC) curves.

Results

The study found that a high sFlt-1/PlGF ratio (> 38) was significantly associated with an increased likelihood of adverse fetomaternal outcomes. The high ratio group had a higher incidence of preeclampsia (75% vs. 20%, p = 0.0012), fetal growth restriction (65% vs. 5%, p = 0.0001), and a shorter enrolment and delivery period (median 13.5 vs. 23 days, p = 0.04884). ROC analysis demonstrated strong predictive performance with an area under the curve of 0.892, indicating high accuracy in identifying patients at risk for adverse outcomes.

Conclusion

The sFlt-1/PlGF ratio effectively stratified patients into high risk and low risk categories for adverse fetomaternal outcomes. This study supports the integration of the sFlt-1/PlGF ratio into clinical practice to enhance risk assessment and decision making in managing HDP.

Implications in Clinical Practice

This study highlights the clinical utility of the sFlt-1/PlGF ratio in the management of HDP. By effectively stratifying patients into high risk and low risk categories, this biomarker enables targeted surveillance and intervention, reducing unnecessary hospital admissions and improving maternal and fetal outcomes. Its integration into routine prenatal care can enhance risk assessment and optimize resource allocation, particularly in low resource settings.

Keywords

preeclampsia - hypertensive disorders of pregnancy - sFlt-1/PlGF ratio - preterm delivery - fetal growth restriction

Authors' Contributions

T.G. and K.A.S. led the study design. T.G., K.A.S., A.R., and G.W. contributed to data collection and interpretation. T.G. performed the statistical analysis and drafted the manuscript. V.D., K.A.S., and A.R. critically reviewed and approved the final version.


Ethical Approval

This study was approved by the Institutional Ethics Committee of AIIMS, New Delhi (Approval No. AIIMSA2325/7.10.2024) and the study adhered to the principles of the Helsinki Declaration.




Publikationsverlauf

Artikel online veröffentlicht:
15. Mai 2025

© 2025. Society of Fetal Medicine. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170 (01) 1-7
    CrossrefPubMedSuche in Google Scholar
  • 2 Arechvo A, Voicu D, Gil MM, Syngelaki A, Akolekar R, Nicolaides KH. Maternal race and pre-eclampsia: cohort study and systematic review with meta-analysis. BJOG 2022; 129 (12) 2082-2093
    PubMedSuche in Google Scholar
  • 3 Dhinwa M, Gawande K, Jha N, Anjali M, Bhadoria AS, Sinha S. Prevalence of hypertensive disorders of pregnancy in India: a systematic review and meta-analysis. Journal of Medical Evidence. 2021; 2 (02) 105-112
    Suche in Google Scholar
  • 4 Karumanchi SA. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension 2016; 67 (06) 1072-1079
    PubMedSuche in Google Scholar
  • 5 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (05) 649-658
    CrossrefPubMedSuche in Google Scholar
  • 6 Venkatesha S, Toporsian M, Lam C. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12 (06) 642-649
    CrossrefPubMedSuche in Google Scholar
  • 7 Dröge LA, Perschel FH, Stütz N. et al. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study. Hypertension 2021; 77 (02) 461-471
    CrossrefPubMedSuche in Google Scholar
  • 8 Soundararajan R, Suresh SC, Mueller A. et al. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens 2021; 23: 97-103
    PubMedSuche in Google Scholar
  • 9 Zeisler H, Llurba E, Chantraine F. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016; 374 (01) 13-22
    CrossrefPubMedSuche in Google Scholar
  • 10 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135 (06) 1492-1495
    CrossrefPubMedSuche in Google Scholar
  • 11 Lees CC, Stampalija T, Baschat A. et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56 (02) 298-312
    CrossrefPubMedSuche in Google Scholar
  • 12 Klein E, Schlembach D, Ramoni A. et al. Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia. PLoS One 2016; 11 (05) e0156013
    CrossrefPubMedSuche in Google Scholar
  • 13 Zeisler H, Llurba E, Chantraine FJ. et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol 2019; 53 (03) 367-375
    CrossrefPubMedSuche in Google Scholar
  • 14 Tataru-Copos AF, Popescu MI, Murvai R, El Kharoubi A. Efficiency of sFlt-1/PlGF ratio in preeclampsia diagnosis. Medicina (Kaunas) 2022; 58 (09) 1196
    PubMedSuche in Google Scholar
  • 15 Pant V, Yadav BK, Sharma J. A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth 2019; 19 (01) 266
    PubMedSuche in Google Scholar
  • 16 Jeon HR, Jeong DH, Lee JY, Woo EY, Shin GT, Kim SY. sFlt-1/PlGF ratio as a predictive and prognostic marker for preeclampsia. J Obstet Gynaecol Res 2021; 47 (07) 2318-2323
    PubMedSuche in Google Scholar
  • 17 Arenas GA, Tang NY, Mueller A. et al. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Am J Obstet Gynecol MFM 2021; 3 (04) 100394
    PubMedSuche in Google Scholar
  • 18 Bian X, Biswas A, Huang X. et al. Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia. Hypertension 2019; 74 (01) 164-172
    PubMedSuche in Google Scholar
  • 19 Rana S, Powe CE, Salahuddin S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125 (07) 911-919
    CrossrefPubMedSuche in Google Scholar
  • 20 Quezada MS, Rodríguez-Calvo J, Villalaín C, Gómez-Arriaga PI, Galindo A, Herraiz I. sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow. Ultrasound Obstet Gynecol 2020; 56 (04) 549-556
    PubMedSuche in Google Scholar
  • 21 Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL. et al. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore) 2017; 96 (04) e6005
    PubMedSuche in Google Scholar
  • 22 Sotiriadis A, Petousis S, Thilaganathan B. et al. Maternal and perinatal outcomes after elective induction of labor at 39 weeks in uncomplicated singleton pregnancy: a meta-analysis. Ultrasound Obstet Gynecol 2019; 53 (01) 26-35
    CrossrefPubMedSuche in Google Scholar
  • 23 Garcia-Manau P, Mendoza M, Bonacina E. et al. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age. Acta Obstet Gynecol Scand 2021; 100 (01) 119-128
    PubMedSuche in Google Scholar
  • 24 Kumar N, Das V, Agarwal A, Agrawal S. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population. AJOG Glob Rep 2023; 3 (02) 100177
    PubMedSuche in Google Scholar